» Articles » PMID: 36705051

Efficacy of Pre-emptive Kidney Transplantation for Adults with End-stage Kidney Disease: a Systematic Review and Meta-analysis

Overview
Journal Ren Fail
Publisher Informa Healthcare
Date 2023 Jan 27
PMID 36705051
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pre-emptive kidney transplantation (PEKT), i.e., transplantation performed before initiation of maintenance dialysis, is considered an ideal renal replacement therapy because there is no exposure to long-term dialysis therapy. Therefore, we summarized advantages/disadvantages of PEKT to assist in deciding whether kidney transplantation should be performed pre-emptively.

Methods: This study was registered with PROSPERO, CRD42021269163. Observational studies comparing clinical outcomes between PEKT and non-PEKT were included; those involving only pediatric recipients or simultaneous multi-organ transplantations were excluded. The PubMed/MEDLINE, Cochrane Library, and Ichushi-Web databases were searched on 1 August 2021. Studies were pooled using the generic inverse-variance method with random effects model, and risk of bias was assessed using ROBINS-I.

Results: Seventy-six studies were included in the systematic review (sample size, 23-121,853; enrollment year, 1968-2019). PEKT patients had lower all-cause mortality (adjusted HR: 0.78 [95% CI 0.66-0.92]), and lower death-censored graft failure (0.81 [0.67-0.98]). Unadjusted RRs for the following outcomes were comparable between the two patient groups: cardiovascular disease, 0.90 (0.58-1.40); biopsy-proven acute rejection, 0.75 (0.55-1.03); cytomegalovirus infection, 1.04 (0.85-1.29); and urinary tract infection, 0.89 (0.61-1.29). Mean differences in post-transplant QOL score were comparable in both groups. The certainty of evidence for mortality and graft failure was moderate and that for other outcomes was very low following the GRADE classification.

Conclusions: The present meta-analysis shows the potential benefits of PEKT, especially regarding patient and graft survival, and therefore PEKT is recommended for adults with end-stage kidney disease.

Citing Articles

Evaluating the efficacy of basiliximab versus no induction in low-immunological-risk kidney transplant recipients: a propensity score matched analysis.

Zhang D, Wen J, Dong J, Ma R, Li S, Wu J Ren Fail. 2025; 47(1):2460729.

PMID: 39978365 PMC: 11843659. DOI: 10.1080/0886022X.2025.2460729.


Push toward pre-emptive kidney transplantation - for sure?.

Cseprekal O, Jacquelinet C, Massy Z Clin Kidney J. 2024; 17(12):sfae335.

PMID: 39698373 PMC: 11653007. DOI: 10.1093/ckj/sfae335.


Promising Results of Kidney Transplantation From Donors Following Euthanasia During 10-Year Follow-Up: A Nationwide Cohort Study.

Susanna C, van Dijk N, de Jongh W, Verberght H, van Mook W, Bollen J Transpl Int. 2024; 37:13142.

PMID: 39494307 PMC: 11528710. DOI: 10.3389/ti.2024.13142.


Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort.

Toapanta N, Comas J, Revuelta I, Manonelles A, Facundo C, Perez-Saez M Transpl Int. 2024; 37:13452.

PMID: 39263600 PMC: 11387891. DOI: 10.3389/ti.2024.13452.


Impact of Dialysis Time on Long-term Outcomes in HLA-identical Living Donor Kidney Transplant Recipients.

Ferreira E, Requiao-Moura L, Nakamura M, Foresto R, Pestana J, Tedesco-Silva H Transplant Direct. 2024; 10(9):e1703.

PMID: 39188532 PMC: 11346849. DOI: 10.1097/TXD.0000000000001703.


References
1.
Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D . Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011; 11(10):2093-109. DOI: 10.1111/j.1600-6143.2011.03686.x. View

2.
Schunemann H, Cuello C, Akl E, Mustafa R, Meerpohl J, Thayer K . GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2018; 111:105-114. PMC: 6692166. DOI: 10.1016/j.jclinepi.2018.01.012. View

3.
Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P . Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002; 17(9):1684-8. DOI: 10.1093/ndt/17.9.1684. View

4.
de Jager D, Grootendorst D, Jager K, van Dijk P, Tomas L, Ansell D . Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009; 302(16):1782-9. DOI: 10.1001/jama.2009.1488. View

5.
Ku E, McCulloch C, Ahearn P, Grimes B, Mitsnefes M . Trends in Cardiovascular Mortality Among a Cohort of Children and Young Adults Starting Dialysis in 1995 to 2015. JAMA Netw Open. 2020; 3(9):e2016197. PMC: 7489869. DOI: 10.1001/jamanetworkopen.2020.16197. View